EBS - Is There Any Hope Left for Emergent BioSolutions?
Emergent BioSolutions ' (NYSE: EBS) streak as a hot coronavirus stock recently came to an abrupt end, after the company ran into problems with its coronavirus vaccine manufacturing contracts. In a little over two months, it is down nearly 50% from its February highs.
With its price-to-earnings (P/E) ratio at 11, the lowest it's been in a year, the stock looks ridiculously cheap . But that's not enough, alone, to justify a purchase. There are still plenty of reasons why investors should stay away from this value trap.
Image source: Getty Images.
For further details see:
Is There Any Hope Left for Emergent BioSolutions?